Oral brivudin versus intravenous acyclovir in the treatment of severe herpes zoster in cancer patients

BRIVUDIN: BVDU: (E)-5-(2-bromovinyl)-2’-deoxyuridineorally 125 mg x 4 per day for 5 days

ACYCLOVIR: ACV: 9-(2-hydroxyethoxymethyl)guanineintravenously 10 mg/kg x 3 per day for 5 days

Multicentered, double-blind, randomized

BVDU group (24 patients) also received placebo i.v.

ACV group (23 patients) also received placebo p.o.

Wutzler et al., J. Med. Virol. 46: 252-257 (1995)

Previous slide

Next slide

Back to first slide

View graphic version